US3707475A
(en)
|
1970-11-16 |
1972-12-26 |
Pfizer |
Antiinflammatory imidazoles
|
DE3029376A1
(de)
|
1980-07-31 |
1982-03-18 |
Nepera Chemical Co. Inc., Harriman, N.Y. |
Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
|
DE3486009T2
(de)
|
1983-09-09 |
1993-04-15 |
Takeda Chemical Industries Ltd |
5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
|
JP2722586B2
(ja)
|
1989-01-13 |
1998-03-04 |
大正製薬株式会社 |
インドリルイミダゾール誘導体
|
JP2808460B2
(ja)
|
1989-11-16 |
1998-10-08 |
大正製薬株式会社 |
イミダゾール誘導体
|
US6358932B1
(en)
|
1994-05-31 |
2002-03-19 |
Isis Pharmaceticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
US5717100A
(en)
|
1995-10-06 |
1998-02-10 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
GB2306108A
(en)
|
1995-10-13 |
1997-04-30 |
Merck & Co Inc |
Treatment of Raf-mediated cancers with imidazole derivatives
|
AU4618497A
(en)
|
1996-08-27 |
1998-03-19 |
Novartis Ag |
Herbicidal s-substituted 1,2,4,6-thiatriazines
|
WO1998038984A2
(en)
|
1997-03-05 |
1998-09-11 |
Sugen, Inc. |
Formulations for hydrophobic pharmaceutical agents
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
GB9711650D0
(en)
|
1997-06-05 |
1997-07-30 |
Pfizer Ltd |
Compounds useful in therapy
|
GB9716557D0
(en)
|
1997-08-06 |
1997-10-08 |
Glaxo Group Ltd |
Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
JP2002541253A
(ja)
|
1999-04-09 |
2002-12-03 |
スミスクライン・ビーチャム・コーポレイション |
トリアリールイミダゾール
|
EP3222619A1
(en)
|
1999-04-15 |
2017-09-27 |
Bristol-Myers Squibb Holdings Ireland |
Cyclic protein tyrosine kinase inhibitors
|
JP2000302680A
(ja)
|
1999-04-23 |
2000-10-31 |
Takeda Chem Ind Ltd |
脳保護剤
|
ATE339406T1
(de)
|
1999-09-23 |
2006-10-15 |
Astrazeneca Ab |
Chinazoline verbindungen als heilmittel
|
TR200201364T2
(tr)
|
1999-11-22 |
2002-10-21 |
Smithkline Beecham P. L. C. |
Yeni bileşikler.
|
ES2222336T3
(es)
|
2000-01-18 |
2005-02-01 |
Vertex Pharma |
Inhibidores de girasas y sus usos.
|
WO2001052846A1
(en)
|
2000-01-18 |
2001-07-26 |
Vertex Pharmaceuticals Incorporated |
Gyrase inhibitors and uses thereof
|
AR029803A1
(es)
|
2000-02-21 |
2003-07-16 |
Smithkline Beecham Plc |
Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
|
US7235658B2
(en)
|
2000-03-06 |
2007-06-26 |
Smithkline Beecham P.L.C. |
Imidazol derivatives as Raf kinase inhibitors
|
GB0005357D0
(en)
|
2000-03-06 |
2000-04-26 |
Smithkline Beecham Plc |
Compounds
|
GB0007405D0
(en)
|
2000-03-27 |
2000-05-17 |
Smithkline Beecham Corp |
Compounds
|
AU2001244618A1
(en)
|
2000-03-30 |
2001-10-15 |
Takeda Chemical Industries Ltd. |
Substituted 1,3-thiazole compounds, their production and use
|
US6608053B2
(en)
|
2000-04-27 |
2003-08-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused heteroaryl derivatives
|
DE60137426D1
(de)
|
2000-06-12 |
2009-03-05 |
Eisai R&D Man Co Ltd |
1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung
|
GEP20053496B
(en)
|
2000-07-19 |
2005-04-25 |
Warner Lambert Co |
Oxygenated Esters of 4-Iodo Phenylamino Benzhydroxamic Acids
|
WO2002042273A2
(en)
|
2000-11-07 |
2002-05-30 |
Bristol-Myers Squibb Company |
Acid derivatives useful as serine protease inhibitors
|
DE60129154T2
(de)
|
2000-11-20 |
2008-02-28 |
Smithkline Beecham Corp. |
Neuartige verbindungen
|
EP1341771A2
(en)
|
2000-11-29 |
2003-09-10 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
JP4267920B2
(ja)
|
2001-01-26 |
2009-05-27 |
中外製薬株式会社 |
代謝調節剤として有用なマロニル−CoA脱炭酸酵素阻害剤
|
WO2002062792A1
(fr)
|
2001-02-02 |
2002-08-15 |
Takeda Chemical Industries, Ltd. |
Inhibiteur de jnk
|
US20030009034A1
(en)
|
2001-03-22 |
2003-01-09 |
Neil Wishart |
Transition metal mediated process
|
JP2002338537A
(ja)
|
2001-05-16 |
2002-11-27 |
Mitsubishi Pharma Corp |
アミド化合物およびその医薬用途
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
GB0129260D0
(en)
|
2001-12-06 |
2002-01-23 |
Eisai London Res Lab Ltd |
Pharmaceutical compositions and their uses
|
US8299108B2
(en)
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
IL164302A0
(en)
|
2002-03-29 |
2005-12-18 |
Chiron Corp |
Substituted benzazoles and use thereof as raf kinase inhibitors
|
AR039241A1
(es)
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
ES2325687T3
(es)
|
2002-09-18 |
2009-09-14 |
Pfizer Products Inc. |
Compuestos de imidazol novedosos como inhibidores del factor de crecimiento transformante (tgf).
|
WO2004026863A1
(en)
|
2002-09-18 |
2004-04-01 |
Pfizer Products Inc. |
Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
|
US7531553B2
(en)
|
2003-03-21 |
2009-05-12 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
AR045944A1
(es)
|
2003-09-24 |
2005-11-16 |
Novartis Ag |
Derivados de isoquinolina 1.4-disustituidas
|
CA2542105C
(en)
|
2003-10-08 |
2011-08-02 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
KR20060118472A
(ko)
|
2003-10-16 |
2006-11-23 |
카이론 코포레이션 |
치환 벤자졸 및 raf 키나아제의 저해제로서 그것의 사용
|
DK1692113T3
(en)
|
2003-11-14 |
2018-01-08 |
Lorus Therapeutics Inc |
ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
|
RU2367661C2
(ru)
|
2004-03-05 |
2009-09-20 |
Тайсо Фармасьютикал Ко., Лтд. |
Производные тиазола
|
KR100749566B1
(ko)
|
2004-04-21 |
2007-08-16 |
이화여자대학교 산학협력단 |
Alk5 및/또는 alk4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
|
WO2005105814A1
(en)
|
2004-04-28 |
2005-11-10 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
PE20060315A1
(es)
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de tiazol como moduladores de ppar
|
PL2298768T3
(pl)
|
2004-06-11 |
2013-03-29 |
Japan Tobacco Inc |
Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu
|
US7453002B2
(en)
|
2004-06-15 |
2008-11-18 |
Bristol-Myers Squibb Company |
Five-membered heterocycles useful as serine protease inhibitors
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
GB0415367D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
AU2005280168A1
(en)
|
2004-08-31 |
2006-03-09 |
Biogen Idec Ma Inc. |
Pyrimidinylimidazoles as TGF-beta inhibitors
|
WO2006038734A1
(en)
|
2004-10-08 |
2006-04-13 |
Astellas Pharma Inc. |
Pyridazinone derivatives cytokines inhibitors
|
CA2584248A1
(en)
|
2004-10-15 |
2006-04-27 |
Biogen Idec Ma Inc. |
Methods of treating vascular injuries
|
JP2007246520A
(ja)
|
2006-02-15 |
2007-09-27 |
Takeda Yuichiro |
Rage阻害剤
|
CA2682189C
(en)
|
2006-04-07 |
2015-12-08 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
|
NZ575274A
(en)
|
2006-08-08 |
2010-11-26 |
Chugai Pharmaceutical Co Ltd |
Pyrimidine derivative as pi3k inhibitor and use thereof
|
WO2008071605A2
(en)
|
2006-12-15 |
2008-06-19 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
DK2170848T3
(en)
|
2007-06-27 |
2015-01-05 |
Astrazeneca Ab |
Pyrazinonderivater and their use to treat lung diseases
|
JP2010532381A
(ja)
|
2007-06-29 |
2010-10-07 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
Rafキナーゼ阻害剤として有用な複素環式化合物
|
CL2008001933A1
(es)
|
2007-06-29 |
2009-09-25 |
Millennium Pharm Inc |
Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
|
JP2010531850A
(ja)
|
2007-07-02 |
2010-09-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規化合物
|
JP2010533159A
(ja)
|
2007-07-09 |
2010-10-21 |
アストラゼネカ アクチボラグ |
化合物947
|
US20100190777A1
(en)
|
2007-07-17 |
2010-07-29 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
JP5241834B2
(ja)
|
2007-07-19 |
2013-07-17 |
メルク・シャープ・アンド・ドーム・コーポレーション |
プロテインキナーゼ阻害剤としての複素環アミド化合物
|
JP2010538003A
(ja)
|
2007-08-29 |
2010-12-09 |
グラクソスミスクライン エルエルシー |
チアゾールおよびオキサゾールキナーゼ阻害薬
|
UY31322A1
(es)
|
2007-09-05 |
2009-04-30 |
|
Amidas heterocíclicas y sus métodos de uso-975
|
WO2009047163A1
(en)
|
2007-10-10 |
2009-04-16 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
TW200940537A
(en)
|
2008-02-26 |
2009-10-01 |
Astrazeneca Ab |
Heterocyclic urea derivatives and methods of use thereof
|
MX2010010317A
(es)
|
2008-03-21 |
2010-10-04 |
Novartis Ag |
Compuestos heterociclicos novedosos y usos de los mismos.
|
US8865732B2
(en)
|
2008-03-21 |
2014-10-21 |
Novartis Ag |
Heterocyclic compounds and uses thereof
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
US20110144107A1
(en)
|
2008-06-11 |
2011-06-16 |
Irm Llc |
Compounds and compositions useful for the treatment of malaria
|
PT2324008E
(pt)
|
2008-07-24 |
2012-06-25 |
Nerviano Medical Sciences Srl |
3,4-diarilpirazoles como inibidores da proteína quinase
|
KR101353857B1
(ko)
|
2008-08-22 |
2014-01-21 |
노파르티스 아게 |
Cdk 억제제로서 피롤로피리미딘 화합물
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
LT3354650T
(lt)
|
2008-12-19 |
2022-06-27 |
Vertex Pharmaceuticals Incorporated |
Junginiai, naudingi kaip atr kinazės inhibitoriai
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
US20110130380A1
(en)
|
2009-09-04 |
2011-06-02 |
Barsanti Paul A |
Heteroaryl Kinase Inhibitors
|
WO2011059610A1
(en)
|
2009-11-10 |
2011-05-19 |
Glaxosmithkline Llc |
Benzene sulfonamide thiazole and oxazole compounds
|
PL2520575T3
(pl)
|
2009-12-28 |
2017-05-31 |
General Incorporated Association Pharma Valley Project Supporting Organization |
Związek 1,3,4-oksadiazolo-2-karboksyamidowy
|
US9315491B2
(en)
|
2009-12-28 |
2016-04-19 |
Development Center For Biotechnology |
Pyrimidine compounds as mTOR and PI3K inhibitors
|
KR20110123657A
(ko)
|
2010-05-07 |
2011-11-15 |
에스케이케미칼주식회사 |
피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
|
JP2013529619A
(ja)
|
2010-06-25 |
2013-07-22 |
ノバルティス アーゲー |
タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物
|
US20130165456A1
(en)
|
2010-08-26 |
2013-06-27 |
Tona M. Gilmer |
Combination
|
CN101993415B
(zh)
|
2010-09-15 |
2013-08-14 |
北京韩美药品有限公司 |
作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
|
AR083797A1
(es)
|
2010-11-10 |
2013-03-20 |
Novartis Ag |
Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
|
EA028821B9
(ru)
|
2011-02-07 |
2018-10-31 |
Плексксикон, Инк. |
Соединения и способы для модуляции киназ, а также показания к их применению
|
EP2739143B1
(en)
|
2011-08-05 |
2018-07-11 |
Gary A. Flynn |
Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
|
PT2751104T
(pt)
|
2011-09-01 |
2019-12-16 |
Novartis Ag |
Compostos e composições como inibidores de c-kit quinase
|
EP2758379B1
(en)
|
2011-09-21 |
2016-10-19 |
Cellzome Limited |
Urea and carbamate derivatives of 2-morpholino-1,3,5-triazine as mTOR inhibitors for the treatment of immunological or proliferative diseases
|
US9399638B2
(en)
|
2012-05-02 |
2016-07-26 |
Lupin Limited |
Substituted pyridine compounds as CRAC modulators
|
AU2013261128B2
(en)
|
2012-05-15 |
2015-11-12 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
TW201414704A
(zh)
|
2012-07-02 |
2014-04-16 |
Biogen Idec Inc |
作爲ROR-γ受體之反向促效劑之含聯芳化合物
|
AR091876A1
(es)
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
SI2882440T1
(sl)
*
|
2012-08-07 |
2019-05-31 |
Novartis Ag |
Farmacevtske kombinacije, ki vsebujejo inhibitor B-RAF, inhibitor EGFR in neobvezno inhibitor PI3K-alfa
|
DK2892535T3
(da)
|
2012-09-04 |
2022-01-03 |
Novartis Ag |
Fremgangsmåde til adjuverende cancerbehandling
|
AU2013323360B2
(en)
|
2012-09-28 |
2017-09-07 |
Cancer Research Technology Limited |
Azaquinazoline inhibitors of atypical protein kinase C
|
US9586948B2
(en)
|
2012-10-08 |
2017-03-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
US9867825B2
(en)
*
|
2012-12-20 |
2018-01-16 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
US9242969B2
(en)
*
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
MX2015013466A
(es)
*
|
2013-03-21 |
2016-06-21 |
Novartis Ag |
Terapia de combinacion que comprende un inhibidor deb-raf y un segundo inhibidor.
|
EA032754B1
(ru)
*
|
2013-11-01 |
2019-07-31 |
Новартис Аг |
Аминогетероарил бензамиды в качестве ингибиторов киназы
|
WO2015095819A2
(en)
|
2013-12-20 |
2015-06-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatment using combinations of erk and raf inhibitors
|
EP3191478B1
(en)
|
2014-09-12 |
2019-05-08 |
Novartis AG |
Compounds and compositions as raf kinase inhibitors
|
UY36294A
(es)
*
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
ES2844211T3
(es)
|
2014-09-12 |
2021-07-21 |
Novartis Ag |
Compuestos y composiciones en calidad de inhibidores de quinasa
|
WO2016115376A1
(en)
*
|
2015-01-14 |
2016-07-21 |
The Regents Of The University Of California |
Detection and treatment of double drug resistant melanomas
|
SI3319993T1
(sl)
|
2015-07-10 |
2020-06-30 |
Genmab A/S |
AXL-specifični konjugati zdravila s protitelesom za zdravljenje raka
|
US20180250302A1
(en)
|
2015-08-28 |
2018-09-06 |
Giordano Caponigro |
Combination of ribociclib and dabrafenib for treating or preventing cancer
|
CN108348514A
(zh)
*
|
2015-08-28 |
2018-07-31 |
诺华股份有限公司 |
含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
|
SG11201810793XA
(en)
*
|
2016-06-03 |
2018-12-28 |
Giordano Caponigro |
Pharmaceutical combinations
|
JP2019517549A
(ja)
*
|
2016-06-10 |
2019-06-24 |
ノバルティス アーゲー |
C−raf阻害薬の治療的使用
|
ES2974991T3
(es)
*
|
2016-09-19 |
2024-07-02 |
Novartis Ag |
Combinaciones terapéuticas que comprenden un inhibidor de RAF y un inhibidor de ERK
|
US11590133B2
(en)
|
2016-12-11 |
2023-02-28 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for treatment of BRAF mutant cancers
|
KR102641827B1
(ko)
|
2017-05-02 |
2024-03-04 |
노파르티스 아게 |
병용 요법
|
US20210085663A1
(en)
|
2017-05-16 |
2021-03-25 |
Biomed Valley Discoveries, Inc. |
Compositions and methods for treating cancer with atypical braf mutations
|
WO2020046966A1
(en)
|
2018-08-27 |
2020-03-05 |
Kura Oncology, Inc. |
Treatment of adenocarcinomas with mapk pathway inhibitors
|
AU2019407159A1
(en)
|
2018-12-20 |
2021-07-15 |
Novartis Ag |
Combination therapy with a Raf inhibitor and a CKD4/6 inhibitor for use in the treatment of cancer
|
BR112021022335A2
(pt)
|
2019-05-13 |
2021-12-28 |
Novartis Ag |
Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
|
US20230226030A1
(en)
|
2020-02-18 |
2023-07-20 |
Novartis Ag |
Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
|
WO2021229439A1
(en)
|
2020-05-12 |
2021-11-18 |
Novartis Ag |
Therapeutic combinations comprising a craf inhibitor
|